Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533942) titled 'A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma' on April 10.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jazz Pharmaceuticals

Condition: Meningioma

Intervention: Drug: JZP3507

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: June 1, 2026

Target Sample Size: 30

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07533942

Disclaimer: Curated by HT Syndication....